PubMed

External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

Booth CM, Dranitsaris G, Gainford MC, Berry S, Fralick M, Fralick J, Sue J, Clemons M.

BMC Cancer. 2007 Jun 28;7:110. Review.PMID: 17598896 [PubMed - indexed for MEDLINE]Related articlesFree article

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.

BMC Cancer. 2007 Aug 8;7:153. Review.PMID: 17686164 [PubMed - indexed for MEDLINE]Related articlesFree article

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.PMID: 16971734 [PubMed - indexed for MEDLINE]Related articlesFree article

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review.

Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H.

Cancer Treat Rev. 2008 Oct;34(6):539-57. Epub 2008 May 27. Review.PMID: 18502589 [PubMed - indexed for MEDLINE]Related articles

Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.

Conte P, Guarneri V, Bengala C.

Clin Breast Cancer. 2007 Dec;7(11):841-9. Review.PMID: 18269773 [PubMed - indexed for MEDLINE]Related articles

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.PMID: 17993229 [PubMed - indexed for MEDLINE]Related articles

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.

Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP.

Cancer. 2007 Sep 1;110(5):965-72.PMID: 17614302 [PubMed - indexed for MEDLINE]Related articlesFree article

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.PMID: 17610808 [PubMed - indexed for MEDLINE]Related articlesFree article

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S.

Oncologist. 2008 Jun;13(6):620-30. Review.PMID: 18586917 [PubMed - indexed for MEDLINE]Related articlesFree article

[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]

Huober J, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G.

Zentralbl Gynakol. 2006 Feb;128(1):30-7. German. PMID: 16450285 [PubMed - indexed for MEDLINE]Related articles

Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.

Colozza M, de Azambuja E, Cardoso F, Bernard C, Piccart MJ.

Oncologist. 2006 Feb;11(2):111-25. Review.PMID: 16476832 [PubMed - indexed for MEDLINE]Related articlesFree article

The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.

Norum J.

Expert Opin Pharmacother. 2006 Aug;7(12):1617-25.PMID: 16872264 [PubMed - indexed for MEDLINE]Related articles

Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing.

Hicks DG, Kulkarni S.

Arch Pathol Lab Med. 2008 Jun;132(6):1008-15. Review.PMID: 18517261 [PubMed - indexed for MEDLINE]Related articles

Priority-setting decisions for new cancer drugs: a qualitative case study.

Martin DK, Pater JL, Singer PA.

Lancet. 2001 Nov 17;358(9294):1676-81.PMID: 11728542 [PubMed - indexed for MEDLINE]Related articles

The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.

Breast Cancer Res Treat. 2008 Jun;109(3):559-66. Epub 2007 Jul 28.PMID: 17661170 [PubMed - indexed for MEDLINE]Related articles

Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

Jahanzeb M.

Clin Ther. 2007 Aug;29(8):1535-47. Review.PMID: 17919537 [PubMed - indexed for MEDLINE]Related articles

Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage.

Wilson PM, Booth AM, Eastwood A, Watt IS.

J R Soc Med. 2008 Mar;101(3):125-32.PMID: 18344469 [PubMed - indexed for MEDLINE]Related articlesFree article

[Medical treatment of primary breast cancer: new targeted biological treatments]

Andersson M, Nielsen DL.

Ugeskr Laeger. 2007 Sep 10;169(37):3082-4. Danish. PMID: 17877953 [PubMed - indexed for MEDLINE]Related articles

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.

Nishimura R, Okumura Y, Arima N.

Breast Cancer. 2008;15(1):57-64.PMID: 18224396 [PubMed - indexed for MEDLINE]Related articles

Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.

McKeage K, Lyseng-Williamson KA.

Pharmacoeconomics. 2008;26(8):699-719. Review.PMID: 18620462 [PubMed - indexed for MEDLINE]Related articles